

prication No.:

10/018,321

December 12, 2001

Inventor:

M. Shiraishi

For:

Benzazepine Derivative, Production and Use

Thereof

Atty. Dkt. No.

2614 US0P

Art Unit:

unassigned ·

Examiner:

unassigned

Allowed:

Batch:

Paper No.:

SECOND PRELIMINARY AMENDMENT

Commissioner for Patents Washington, D.C. 20231

Dear Sir:

. Nj

In connection with the filing of the above-identified U.S. national phase application, please consider the following amendment and remarks.

AMENDMENT

In the Specification

Please insert the following paragraph as the second paragraph on page 2 of the specification.

Page 2, paragraph 2 (AMENDED)

B1

In order to investigate an anti-AIDS drug having CCR5 antagonistic activity, it is necessary to clone CCR5 gene from human tissue derived cDNA library, to ligate said gene with a vector for expression in animal cells, to introduce said gene into animal cells and to obtain cells expressing CCR5. In addition, with using this transformant, it is necessary to screen a compound which strongly inhibits binding of CC chemokine RANTES, natural ligand, to CCR5. However, so far there has been almost no report of a low molecular weight compound which has

Please type a plus sign (+) inside this box + PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
The Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission 66

Application Number	10/018,321	
Filing Date	December 12, 2001	
First Named Inventor	M. Shiraishi	
Group Art Unit	unassigned	
Examiner Name	unassigned	
Attorney Docket Number	2614 US0P	

ENCLOSURES (check all that apply)				
	claration(s) Request sent Request ure Statement siority g Parts/	charge any addition	After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please identify below): Return Postcard. er is hereby authorized to onal fees which may be any overpayment to 500799.	
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT				
Firm or Individual name Elaine M. Ramesh, Ph.D., JD, Reg. No. 43,032 Signature Elaine M. Ramesh, Ph.D., JD, Reg. No. 43,032				
1/24/02				
CERTIFICATE OF MAILING				
hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date:				
Typed or printed name Signature		Date	e	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

EXPRESS MAIL # EL 916 492 6.11 45

Certificate of Mailing under 37 CFR 1.10

Express Mail Label No. EL 9164

EL 916492611US

Printed Name: Gail L. Winokur